SCHEMBL2501416

SCHEMBL2501416

CCCOc1cc(COc2cccc([C@@H](C)C(C)C(=O)O)c2)ccc1-c1cc(OC)ccc1F

nearest known ligand 0.57

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 20/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2500878 1.00 FFAR1 (0.57) FFAR1
SCHEMBL2497801 0.97 FFAR1 (0.57) FFAR1
SCHEMBL2496841 0.97 FFAR1 (0.57) FFAR1
SCHEMBL2500317 0.88 FFAR1 (0.73) FFAR1
SCHEMBL2500648 0.88 FFAR1 (0.73) FFAR1
SCHEMBL2494936 0.88 FFAR1 (0.62) FFAR1
SCHEMBL2506429 0.88 FFAR1 (0.62) FFAR1
SCHEMBL2500876 0.86 FFAR1 (0.63) FFAR1
SCHEMBL2501412 0.86 FFAR1 (0.63) FFAR1
SCHEMBL12191819 0.86 FFAR1 (0.62) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed